Iconovo
Iconovo is a Swedish inhalation technology company that develops patented inhaler platforms and drug-delivery concepts for pharmaceutical partners. Its business centers on enabling customers to create new or generic inhaled medicines through outlicensing, development support, and related collaboration agreements.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenuePatented inhaler devices and platform technologies used to deliver dry-powder or intranasal medicines.
Joint projects with pharma partners to adapt drug formulations for Iconovo's devices.
Technology access agreements that can include upfront, milestone, and royalty income.
Early-stage technical work to assess product fit, formulation, and device compatibility.
Customers
Iconovo sells to pharmaceutical companies that want to develop inhaled medicines without building their own inhaler technology from scratch. Its partners include generic drug companies, smaller biotechnology firms, and larger pharmaceutical companies pursuing either novel inhaled therapies or generic versions of established inhalers. Customers buy Iconovo's platforms and development expertise to shorten time-to-market and reduce technical risk in inhalation drug development.
They buy inhaler platforms and development support to launch generic versions of branded inhaled drugs.
They use Iconovo's technology to reformulate drug candidates for inhaled or intranasal delivery.
They partner on novel inhaled medicines and broader platform-based development programs.
They seek specialized inhalation expertise and device compatibility for complex formulation work.
Strategy
Iconovo's strategy is to build value from a portfolio of patented inhaler platforms and convert that IP into multiple partner programs. The company emphasizes both novel and generic inhalation opportunities, using collaborations to diversify risk across markets and development stages. It also seeks to strengthen patent protection and regionalize outlicensing where that can improve deal economics and speed to agreement.
A broader collaboration base reduces dependence on any single project and increases the chance of future license, milestone, and royalty income.
Patent protection supports pricing power, partner confidence, and the ability to license platform technology repeatedly.
Country- or region-specific deal structures can shorten negotiations and improve the value captured from each opportunity.
Geography
Iconovo is headquartered in Lund, Sweden, and operates as a partner to international pharmaceutical companies. Its commercial footprint is global rather than tied to one end-market, with reported collaborations and patent activity spanning Europe, the United States, China, Japan, and other international markets. Geography matters because inhalation products are developed and licensed country by country, and patent protection can differ by region.
Risks
Iconovo depends on customers' willingness to invest in development programs, so deal timing and partner funding can be uneven. The business also relies heavily on specialized personnel and on successful patent protection, both of which are critical in a technology-led licensing model. As with other biotech and medtech platform companies, clinical, regulatory, and formulation complexity can delay projects or reduce the chance that a program reaches commercialization.
- Partner funding and willingness to investImpact: HighLikelihood: High
Sales depend on customers continuing development programs and paying for access, work packages, and milestones.
Exposure - Patent and IP protectionImpact: HighLikelihood: Medium
The business model depends on defensible inhaler platforms and enforceable rights in key markets.
Exposure - Personnel retention and recruitmentImpact: High
The company needs specialized inhalation, formulation, and IP expertise to deliver projects and support partners.
Exposure: R&D and business development functions
- Development and regulatory complexityImpact: MediumLikelihood: High
Inhalation products require formulation, device compatibility, and regulatory success before commercialization.
Exposure: Novel and generic inhalation programs
Accounting
Judgemental itemsIncome may include upfront access fees, development services, milestones, and royalties, each with different recognition timing.
Impact: Can create uneven quarterly revenue and require judgment on performance obligations
Partner receivables and disputed amounts may require provisions or write-downs.
Impact: Affects operating profit and comparability across periods
The value of platform IP depends on future partner success and market adoption.
Impact: Could lead to non-cash charges if expected commercialization weakens
Milestones may be recognized only when achieved and when uncertainty is resolved.
Impact: Can materially shift revenue between periods
Similar listed companies
Publicly listed companies with a comparable business focus.
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Innoviva, Inc.
INVA · Pharmaceutical Preparations
Pulmatrix, Inc.
PULM · Pharmaceutical Preparations
Revenio Group Oyj
REG1V · Medical Devices
Revenio Group Oyj is a Finnish company specializing in comprehensive eye care diagnostic solutions.
Sedana Medical
SEDANA · Health Care
Sedana Medical is a Swedish company based in Danderyd that specializes in developing, manufacturing, and selling medical devices and pharmaceuticals.
Ainos, Inc.
AIMDW · Computer Peripheral Equipment, NEC
Last updated: 24/09/2026